)
Niagen Bioscience (NAGE) investor relations material
Niagen Bioscience A.G.P. Virtual Consumer Showcase summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Business and research
Four business lines span consumer supplements and skincare, ingredient supply, Niagen Plus IV/injections, and pharmaceutical development.
Management cited 52 peer-reviewed clinical studies on NR and 30 more underway; it estimated the global NAD supplement market at $3B, versus $10M 8–10 years earlier.
Management positioned NR as its preferred NAD precursor and cited a Norway study finding NR 2.3x more effective than NMN at elevating NAD.
Consumer products and marketing
Tru Niagen is a ~$100M supplement, sold mainly through Amazon and its website, with Watsons in parts of Asia and limited U.S. retail; Nestlé and Life Extension also sell NR products.
Direct website sales grew more than 30% last year, while sales were flat this year amid lower-priced competitors; management expects supplement growth to resume as awareness and product range expand.
NanoCloud skincare launched after studies indicated topical NR penetrates skin and raises NAD in skin cells; management expects a major skincare partner to launch a widely distributed product in Q1 next year.
Marketing investment has increased and could remain elevated for one or two quarters; a Kelly Slater campaign is intended to build brand awareness.
Ingredient and delivery businesses
Ingredient customers include Nestlé, H&H, and Life Extension; a Goli NR gummy was expected to launch shortly.
Nicotinamide riboside malate is a lower-cost ingredient intended for broader supply to supplement brands; whether to launch it under Tru Niagen remained under review.
Niagen Plus offers pharmaceutical-grade NR through clinics and at-home injection kits; management described the kits as selling, while its plans for aggressive investment in the channel remained undecided.
- A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Q3 sales fell 20% as investment and new launches targeted future growth.NAGE
Q3 2026 - Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGE
LD Micro 20th Annual Main Event Conference - Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE
17th Annual Midwest IDEAS Conference - Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGE
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches.NAGE
Q2 2026 - NB4168 advances NAD science into pharmaceuticals, targeting rare diseases with strong safety data.NAGE
Fireside chat - Advancing NB4168 for rare genetic diseases with strong clinical data and premium market potential.NAGE
Corporate presentation - Record revenue, profitability, and cash flow set the stage for double-digit growth in 2025.NAGE
Q4 2024
)
)
)
)
)
)
)
)